ArticleStem cells translational medicine2014
Tissue-engineered vascular grafts created from human induced pluripotent stem cells.
Article in Stem cells translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Induced Pluripotent Stem Cell-Derived Small-Diameter Vascular Grafts: Scaffold Design, Immune Engineering, and Clinical Translation.Journal of cellular physiology · 2026Review
- Synthetic and Tissue-Engineered Vascular Grafts: Current Status, Emerging Technologies, and Clinical Prospects.Reviews in cardiovascular medicine · 2025Review
- Construction of vascular grafts based on tissue-engineered scaffolds.Materials today. Bio · 2024Review
- Generation of Autologous Vascular Endothelial Cells for Patients with Peripheral Artery Disease.Journal of cardiovascular translational research · 2024Article
- Advances in the differentiation of pluripotent stem cells into vascular cells.World journal of stem cells · 2024Review
- Vascular organoids: unveiling advantages, applications, challenges, and disease modelling strategies.Stem cell research & therapy · 2023Review
- Clinical Application for Tissue Engineering Focused on Materials.Biomedicines · 2022Review
- Article
- 3D culturing of human pluripotent stem cells-derived endothelial cells for vascular regeneration.Theranostics · 2022Article
- Biomaterials as a Vital Frontier for Stem Cell-Based Tissue Regeneration.Frontiers in cell and developmental biology · 2022Review
- Human iPS Cell-derived Tissue Engineered Vascular Graft: Recent Advances and Future Directions.Stem cell reviews and reports · 2021Review
- Challenges and Possibilities of Cell-Based Tissue-Engineered Vascular Grafts.Cyborg and bionic systems (Washington, D.C.) · 2021Review
- Article
- Human iPSCs Stretch to Improve Tissue-Engineered Vascular Grafts.Cell stem cell · 2020Article
- Aortic "Disease-in-a-Dish": Mechanistic Insights and Drug Development Using iPSC-Based Disease Modeling.Frontiers in cell and developmental biology · 2020Review
- Functional characterization of iPSC-derived arterial- and venous-like endothelial cells.Scientific reports · 2019Article
- Modeling elastin-associated vasculopathy with patient induced pluripotent stem cells and tissue engineering.Cellular and molecular life sciences : CMLS · 2019Review
- Stem Cell Sources and Graft Material for Vascular Tissue Engineering.Stem cell reviews and reports · 2018Review
- Tissue Engineering at the Blood-Contacting Surface: A Review of Challenges and Strategies in Vascular Graft Development.Advanced healthcare materials · 2018Review
- In Vivo Performance of Decellularized Vascular Grafts: A Review Article.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The utility of human induced pluripotent stem cells (hiPSCs) to create tissue-engineered vascular grafts was evaluated in this study. hiPSC lines were first induced into a mesenchymal lineage via a neural crest intermediate using a serum-free, chemically defined differentiation scheme. Derived cells exhibited commonly known mesenchymal markers (CD90, CD105, and CD73 and negative marker CD45) and were shown to differentiate into several mesenchymal lineages (osteogenic, chondrogenic, and adipogenic). Functional vascular grafts were then engineered by culturing hiPSC-derived mesenchymal progenitor cells in a pulsatile bioreactor system over 8 weeks to induce smooth muscle cell differentiation and collagenous matrix generation. Histological analyses confirmed layers of calponin-positive smooth muscle cells in a collagen-rich matrix. Mechanical tests revealed that grafts had an average burst pressure of 700 mmHg, which is approximately half that of native veins. Additionally, studies revealed that karyotypically normal mesenchymal stem cell clones led to generation of grafts with predicted features of engineered vascular grafts, whereas derived clones having chromosomal abnormalities generated calcified vessel constructs, possibly because of cell apoptosis during culture. Overall, these results provide significant insight into the utility of hiPS cells for vascular graft generation. They pave the way for creating personalized, patient-specific vascular grafts for surgical applications, as well as for creating experimental models of vascular development and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.